Budoprutug and CD-19
Budoprutug is an anti-CD19 mAb designed to result in durable and potent B cell depletion, based on long dosing intervals, and with potential for intravenous (IV) and subcutaneous (SC) formulations. CD19 is an attractive target relevant to multiple B cell-mediated diseases, as it is expressed across the entire B cell lineage, including autoantibody-secreting cells. The broad CD19 expression profile may enable comprehensive, rapid, and durable depletion of pathogenic B cells, while preserving protective antibody responses mediated by long-lived plasma cells. Targeting CD19 could provide significant clinical benefits compared to other immune cell markers.
Budoprutug is a Highly Potent, Fc-Enhanced Anti-CD19 mAb
Designed for optimal biological activity, with a specialized formulation that may enable the development
of both intravenous and subcutaneous delivery.
A completed budoprutug Phase 1b study demonstrated proof of concept and a favorable safety profile
- Rapid and complete B cell depletion observed in 100% of pMN patients (n=5) at doses of 100-200mg
- Serologic Remission Anti-PLA2R antibody negativity achieved in 100% (3/3) evaluable patients
- Led to Clinical Remission with all patients (5/5) achieving complete or partial clinical remission by Week 48, as measured by Urine Protein Creatine Ratio (UPCR)
- Budoprutug was generally well tolerated at doses of up to 200mg, supporting exploration of higher doses in future studies
Our budoprutug development strategy
We are developing budoprutug across multiple disease categories, pursuing lead indications with high unmet need, clear B-cell driven pathology and large therapeutic and commercial opportunities.
IgG4 Mediated Conditions
Diseases with clear pathophysiology, support targeting of CD19-expressing B cells with demonstrated clinical proof of concept
Single Organ, Orphan Diseases
Diseases for which B cell depletion has demonstrated clinical proof of concept
Complex Systemic Disorders
Multi-organ diseases with a more heterogeneous patient population
The results from ongoing clinical studies will inform the design of later-stage trials and potential additional expansion into new indications.
Clinical Trial
Nullam consectetur blandit augue, vel tempor orci faucibus a. Integer sed eros quis metus fringilla aliquam ac et ipsum. Phasellus lacinia varius enim, nec condimentum leo porttitor a. Duis nunc dolor, eleifend at ultrices sit amet, tristique vitae nisl.